A DARPin targeting activated Mac-1 is a novel diagnostic tool and potential anti-inflammatory agent in myocarditis, sepsis and myocardial infarction

Patrick M. Siegel1,2 · István Bojti1 · Nicole Bassler2 · Jessica Holien3 · Ulrike Flierl1 · Xiaowei Wang2,4,5 · Philipp Waggenshauser1 · Xavier Tonnar1 · Christopher Vedecnik1 · Constanze Lamprecht6 · Ivana Stankova1 · Tian Li1 · Thomas Helbing1 · Dennis Wolf3 · Nathaly Anto-Michel1 · Lucia Sol Mitre1 · Julia Ehrlich3 · Lukas Orlean3 · Ileana Bender1 · Anne Przewosnik1 · Maximilian Mauler1 · Laura Hollederer1 · Martin Moser1 · Christoph Bode1 · Michael W. Parker3,4,7 · Karlheinz Peter2,4,5,8 · Philipp Diehl1,2,5

Received: 31 July 2020 / Accepted: 18 January 2021
© Crown 2021

Abstract
The monocyte β2-integrin Mac-1 is crucial for leukocyte–endothelium interaction, rendering it an attractive therapeutic target for acute and chronic inflammation. Using phage display, a Designed-Ankyrin-Repeat-Protein (DARPin) was selected as a novel binding protein targeting and blocking the αM I-domain, an activation-specific epitope of Mac-1. This DARPin, named F7, specifically binds to activated Mac-1 on mouse and human monocytes as determined by flow cytometry. Homology modelling and docking studies defined distinct interaction sites which were verified by mutagenesis. Intravital microscopy showed reduced leukocyte–endothelium adhesion in mice treated with this DARPin. Using mouse models of sepsis, myocarditis and ischaemia/reperfusion injury, we demonstrate therapeutic anti-inflammatory effects. Finally, the activated Mac-1-specific DARPin is established as a tool to detect monocyte activation in patients receiving extra-corporeal membrane oxygenation, as well as suffering from sepsis and ST-elevation myocardial infarction. The activated Mac-1-specific DARPin F7 binds preferentially to activated monocytes, detects inflammation in critically ill patients, and inhibits monocyte and neutrophil function as an efficient new anti-inflammatory agent.

Keywords DARPin · Inflammation · Myocarditis · Myocardial infarction · ECMO · Sepsis

Introduction
Cardiovascular diseases remain the leading causes of morbidity and mortality worldwide [7]. Activated leukocytes are not only the drivers of vascular inflammation, which is the
underlying cause of cardiovascular diseases such as atherosclerosis, but also of many other inflammatory diseases such as sepsis, arthritis, and auto-immune disease [81]. Adhesion molecules, and in particular leukocyte β2-integrins, play a major role in the interaction of leukocytes with the endothelium, which is an important first step in leukocyte recruitment to inflamed tissues.

Mac-1 (αMβ2, CD11b/CD18, complement receptor 3) is an important member of the β2-integrin family and is highly expressed on monocytes and neutrophils. It interacts with multiple ligands including fibrinogen, C3bi, ICAM-1, and heparin, and is involved in leukocyte adhesion to and migration through the endothelium, phagocytosis, and the innate and adaptive immune system [59]. Like all β2-integrins, Mac-1 is composed of an α-chain (165 kD) and a β-chain (95 kD) [75]. The ectodomains of integrins can adopt a resting and an activated conformation [82]. Cellular activation results in a conformational change of the resting receptor to the activated conformation (via a switchblade mechanism), resulting in exposure of activation-specific ectodomains which mediate high affinity of the activated receptor to several receptor ligands [40]. This activation-specific epitope of the α-chain of Mac-1, the so-called inserted domain (I-domain), thereby mediates several receptor–ligand interactions [20].

Traditional untargeted anti-inflammatory drugs such as steroids or methotrexate have not shown convincing results in cardiovascular diseases and are associated with severe, potentially life-threatening side effects [49]. This imbalance between beneficial effects and side effects may be related to the fact that these anti-inflammatory drugs do not target specific receptor functions but, rather, affect overall leukocyte function. Biologicals such as antibody drugs, in selectively targeting specific cell surface receptors, promise a better ratio of therapeutic effects to nonspecific side effects. A large range of successful antibody drugs targeting surface receptors have been developed as anti-inflammatory and cancer drugs. These drugs bind to specific regions/epitopes in the receptor and can thereby block specific ligand-binding and specific receptor functions [79]. Furthermore, integrin receptors such as Mac-1 are of particular interest for therapeutic targeting as they offer additional specificity by virtue of having an active, ligand-binding conformation. A good example is GPIIb/IIIa where activation-specific antibodies have been shown to avoid classic side effects such as paradoxical platelet activation and prolongation of bleeding time [2]. A similar approach was undertaken for the integrin receptor Mac-1, producing a single-chain antibody (MAN-1) that was specific for the active conformation of Mac-1; however, this antibody did not provide cross-reactivity to the murine Mac-1 and thus could not be tested in a mouse preclinical model and as a consequence was not further developed as a drug candidate [25]. This paper describes a novel approach aiming to develop a biological, highly sought-after anti-inflammatory drug candidate that would allow specific inhibition of the activated conformation of Mac-1.

Designed Ankyrin Repeat Proteins (DARPins) are a novel class of binding molecules derived from naturally occurring ankyrin repeat proteins [69]. They can be selected against multiple types of targets using phage or ribosome display [60]. DARPins offer several advantages over antibody drugs and small binding molecules, such as very high stability over a wide range of temperatures and pH values [78], the possibility of using bacterial expression systems with particularly high yields, ease of purification, and potential large-scale production [9]. Their small size (∼14–21 kD) may also be of advantage in diagnostic or therapeutic applications where increased tissue penetration is required, e.g. tumour therapy, inflammation, and imaging [10]. Due to these advantages, as well as high affinity and specificity binding to their target epitopes, DARPins are very attractive as diagnostic tools and therapeutic agents, and in fact the first DARPins have been successfully established as drugs in clinical applications such as neovascular age-related macular degeneration [50].

We aimed to select a DARPin targeting the ligand-binding site of the β2-integrin Mac-1 and thereby achieve activation-specific blocking of Mac-1, which is a key player in cardiovascular inflammation [80]. A DARPin targeted to the I-domain should block ligand interaction without affecting the function of the resting integrin. This approach would deliver very selective inhibition of the highly pro-inflammatory subpopulation of activated leukocytes, without inhibiting the non-activated majority of leukocytes. As such, we describe an innovative drug candidate that is potentially clinically applicable in a broad range of diseases with inflammatory components.

**Methods**

**Mouse αM I-domain and human αM I-domain**

To select DARPins against the mouse αM I-domain, a DARPin-expressing phage library consisting of 10^10 phages was used [67]. To assess for cross-reactivity, binding of selected anti-αM I-domain (anti-mId) DARPins to the human αM I-domain was investigated in Enzyme-Linked Immunosorbent Assays (ELISA). According to the PubMed data bank, the following sequence was used for the mouse αM I-domain: MVLRPQFGPEALRECPOQEDSIDVFLEDGSQINIDFQKMKFVSTVMQKFFKSSLMLQYSDEFRIHTFNDFKRRSPHRVSPIKQNGRTKTAIGRKVVERRHVKTNGARENAAKILVITDGEKFGDPLYKDVPEADAGVIRYVGAFKNPKQSRRELDTIAKPGHEHFQVDNFALNTIQNQLQEKI-
For the human αM I-domain, the following sequence was used: RQQPQKFPEALRGCPQEDSDIAFLIDGSGSIIPHD-FDRRKMKEFVSTVMEQLKKSTLFSMLQYESEFRI-HFTFKEFQNNPNSRLVKPITQLGRHTATGIRK-VRELFINTGARKNAFKILVITDGEKGDPLGYEDVIPEADREGVIRYVIGDARFRSEKSRQELNTIAKPPRDHVQVNNEFAKLTIQNQLIREKIFAIEGTGSSSSSFEHEMSQGFSAAALEHHHHH.

The human αM I-domain was cloned into the bacterial expression vector pET-20b (+), while the mouse αM I-domain was cloned into the bacterial expression vector pHOG21. Both were expressed in E. coli BL21 DE3 and proteins were purified as described below. To assess conformation-specific binding of DARPin, a mouse αM I-domain mutant (F302L), as described by Hu et al. [36], which represents the activated αM I-domain conformation (a-mIld), was cloned and expressed like the wild-type mouse αM I-domain described above.

The functionality of the recombinant human and mouse αM I-domains was assessed by their binding to human or mouse ICAM-1, respectively, which are physiological ligands of Mac-1. 96-well plates (Maxisorb, Thermo Scientific, USA) were coated with 0.1 μM human or mouse ICAM-1 (R&D Systems, USA) or BSA (Sigma-Aldrich, USA, 30 μM), then recombinant human or mouse αM I-domain binding was quantified with anti-His-HRP staining on an ELISA plate reader at λ 450 nm. The ELISA was designed by the researchers.

**Phage panning using DARPin-expressing phage library**

The phage library used in this project contains a very high diversity of approximately 10^{10} and was kindly provided by Molecular Partners (Zurich, Switzerland). This phage diversity allows selection of high-affinity DARPin against most biological antigens. The affinity of the DARPin phagemids is in the nanomolar range [67]. DARPin phagemid particles contain the phagemid vector pMPAG-3, in which the DARPin encoding insert is located in the Multiple Cloning Site (MCS) between the BamHI and HindIII restriction sites. pMPAG-3 mediates chloramphenicol (CML) resistance, allowing selective growth of only phagemid-infected E. coli cells in CML-containing media/agar plates.

DARPin phages were selected on a soluble and immobilized αM I-domain using phage display standard protocols (Fig. 1a) [15]. Briefly, streptavidin- or neutravidin-coated magnetic beads were blocked with an albumin- and Tween®-containing buffer. After removal of DARPin I-domain complexes were harvested using streptavidin- or neutravidin-coated beads. After several washing steps, phages bound to the I-domain were eluted with a buffer containing glycine (200 mM, pH 2) and samples were neutralized with tris/base (2 M) before being used for infection with log-phase bacteria. Infected E. coli were grown for 30 min without shaking at 37 °C followed by 30 min at 220 rpm (37 °C) before cells were plated out on CML-containing agar plates (overnight, 37 °C). Colonies were harvested and grown in CML-containing media until OD_{600} reached 0.5, then the culture transferred into LB medium containing CML, isopropyl-β-D-thiogalactopuranosid (IPTG; Merck, Germany), and helper phages (overnight, 37 °C). Phagemid particles from the overnight culture were purified by spinning (16,000 g, 4 °C, 20 min) and incubating the supernatant with polyethylenglycol (PEG; Sigma Aldrich, USA) on ice for >1 h. PEG-purified phages were concentrated and used for the next phage-panning round.

**Polyclonal phage ELISA**

To assess the affinity enrichment of the selected phages, a polyclonal phage ELISA was performed after three panning rounds. The biotinylated αM I-domain was placed into neutravidin-coated ELISA wells and phages from the corresponding panning rounds were added. Binding of phages to αM I-domain-coated wells was assessed with an anti-M13 HRP-coupled antibody (100 μl at 1:40,000 dilution, 4 °C, 1 h; GE Lifescience, USA).

**Cloning of DARPin vectors from phage vector into expression vector**

DARPin vectors from the third panning round in the phage vector (pMPAG-3) were digested with BamHI and HindIII (1 h, 37 °C). DARPin-encoding inserts were gel-purified and cloned into the expression vector pMPAG-6 (Molecular Partners, Switzerland). DARPins in pMPAG-6 were transformed into TG-1 cells and the binding behaviour of each transformed clone assessed in a monoclonal DARPin ELISA coated with the αM I-domain.

**Production and purification of DARPin vectors and αM I-domain**

Expression vectors contained a T5 promoter allowing high-level expression of the DARPin vectors in human and mouse αM I-domains in E. coli cells using IPTG. Furthermore, the vectors encode for ampicillin resistance, allowing selective growth in ampicillin-containing media. DARPins applied in mouse models contained an albumin binding domain, which
by its binding to circulating albumin is associated with a half-life in vivo of approximately 1–2 days [68]. We used Luria Broth (LB) medium. After overnight culturing (10 ml in a 50 ml conical tube, 12 h, 37 °C, 220 rpm), clones were grown in LB medium (0.5–1 l; Sigma Aldrich, USA) containing ampicillin (\(F_c = 100 \mu g/ml\)) until \(OD_{600}\) of 0.4–0.7 was reached. After induction with IPTG (\(F_c = 500 \mu M\)), cultures were grown for 5 h (DARPins) or overnight (I-domain). Cells were then harvested (20 min, 4000 g, 8 °C) and stored at −80 °C until purification. AVB 101 cells (Avidity AVItag™, Colorado, USA) were used for expression of biotinylated DARPins enabling in vivo biotinylation of proteins according to the manufacturer’s instructions.
Frozen bacterial pellets were resuspended in Bugbuster Mastermix (Merck, Germany) as recommended by the manufacturer. Recombinant proteins were separated from cellular debris by centrifugation (15 min, 16,000g, 4 °C), captured by Ni²⁺ beads (Qiagen, Germany), washed five times with wash buffers (10 and 20 mM imidazole, Merck, Germany) and eluted with the elution buffer (250 mM imidazole). Eluted recombinant proteins were dialyzed against 2 l of PBS for at least 24 h and used for further experiments.

### SDS- and Western blotting of recombinant proteins

Size and purity of recombinant proteins were assessed in 12% sodium dodecylsulfate polyacrylamide electrophoresis (SDS-PAGE) with Coomassie staining and Western blotting using standard protocols. For Western blots of DARPin, gels were blotted on a polyvinylidene fluoride (PVDF) membrane (Immobilon, Merck Millipore, Germany) before the membrane was blocked with 3% BSA (30 min, 70 rpm, RT). Blotted DARPin and the αM I-domain were detected using an anti-His-Peroxidase antibody (1:8000; Roche Diagnostics, Switzerland) with SuperSignal ECL reagent (Thermo Scientific, USA).

### Flow-cytometric binding assays

DARPin binding to the mouse monocytic cell line RAW 264.7 (ATCC, USA) was determined as follows: 5 × 10⁵ cells were resuspended in 100 µl PBS + Ca²⁺ (0.88 mM) and Mg²⁺ (0.49 mM) and stimulated with phorbol 12-myristate 13-acetate (PMA, Fₐ = 200 ng/ml, 15 min, 37 °C) or PBS + Ca²⁺ and Mg²⁺ as a negative control. RAW 264.7 cells were stained with a FITC anti-CD11b antibody (Clone M1/70, BD, USA), an isotype control antibody or DARPin (Fₐ = 2.5 µg/ml). Gating was performed according to FSC/SSC plots (Online Resource 1).

DARPin binding to monocytes was also assessed in whole mouse or human blood. 100 µl freshly obtained citrated blood was stimulated with PMA, (Fₐ = 200 ng/ml, 15 min, 37 °C) or PBS + Ca²⁺ and Mg²⁺ as negative control, followed by red blood cell lysis (mouse blood: 5 min lysis, human blood: 20 min lysis, on ice; BD FACS lysing solution, USA). Samples were centrifuged (300g, 5 min), washed and resuspended in 100 µl PBS + Ca²⁺ (0.88 mM) and Mg²⁺ (0.49 mM) + 0.1% BSA.

After cells were stained with DARPin for 15 min, mouse monocytes were stained with a Pacific Blue anti-Ly-6C antibody (10 µl, 1:50 dilution; BD Biosciences, USA), DARPin were detected with an Alexa Fluor 488 anti-His-tag antibody (1 µl undiluted; Qiagen, Germany) and cells were fixed (BD CellFIX™, USA). For mouse monocytes, DARPin binding to Ly-6C⁺ monocytes was investigated. For human monocytes Pacific Blue anti-CD16 and APC anti-CD14 antibodies (both: 5 µl, 1:10 dilution; Biolegend, USA) were used for staining and gating and binding to CD14⁺ cells was assessed. FACS was performed within 2 h of sample preparation to prevent degradation of monocyte surface markers.

To investigate specific binding of DARPin F7 to the activated Mac-1 receptor, competitive binding assays of F7 versus conventional anti-Mac-1 antibodies were performed. The protocol was performed as described above with the following alterations: PMA-stimulated leukocytes from freshly obtained human blood were pre-incubated (15 min, RT) with anti-Mac-1 antibodies M1/70 (Fₐ = 50 µg/ml) (Biolegend, USA) or Mab107 (Fₐ = 10, 50, 100 µg/ml) (Absolute Antibody, USA) at different concentrations. Then DARPin (Fₐ = 2.5 µg/ml, 15 min, ice) were added and the protocol was performed as described above.

Activation-specific binding of F7 to activated human CD14⁺ monocytes was also assessed compared to other anti-CD11b antibodies for visual analysis of the “population shift” in the FITC-histogram occurring after PMA-stimulation. Whole blood was prepared and monocytes were stained as described above. CD11b expression and conformational change was detected either with DARPin F7, the scFv MAN-1 (kindly provided by Prof. Karlheinz Peter) which were detected by an Alexa Fluor 488 anti-His-tag antibody (Qiagen, USA) or the following anti-Mac-1 antibodies (Fₐ = 10 µg/ml): Mab107 (Absolute Antibody, USA), 2LPM19c (Santa-Cruz Biotechnology, USA), M1/70, Mab24, CBRM1/5 (all from Biolegend, USA). Antibody binding was detected by appropriate FITC-conjugated secondary antibodies (1 µl, 15 min, RT).

In addition to competitive binding assays, binding competition between recombinant ICAM-1 (rICAM; Biolegend, USA), which is a physiological ligand of Mac-1, and F7 was conducted. Monocytes were isolated from healthy C57BL/6N mice using a monocyte isolation kit (STEM-CELL, France) and stained with F7, PBS or the control DARPin (15 min, RT) followed by incubation with rICAM (15 min, RT). ICAM-1-binding was detected by a FITC anti-ICAM-1 antibody (Biolegend, USA).

When a histogram showed a single-peak monocyte population, the mean fluorescence intensity (MFI) was used as a read-out for DARPin binding (detected by anti-His-tag antibody). When more than one peak in the gated final monocyte population was visible DARPin binding was quantified in percentage. To define the positive population, a gate was set in the FITC histogram including the upper 1–3% of the unstained monocyte population stained with the secondary anti-His antibody. The monocytes stained with DARPin and the secondary antibody shifting into this gate were then recorded in percentages.

For assessment of human neutrophils, approximately 5 × 10⁶ neutrophils were isolated by density gradient
centrifugation from citrated human whole blood using Polymorphprep® (Alere Technologies, Norway). Neutrophils were identified by Pacific-Blue anti-CD66b antibody staining (5 µl; 15 min before acquisition, RT; Biolegend, USA) in the Pacific Blue/SSC gate and verified by back-gating to the FSC/SSC plot. Mean FITC fluorescence intensity was used to monitor DARPin binding. DARPins \((F_c = 2.5 \, \mu g/ml)\) and the secondary antibody (1 µl, Alexa Fluor 488 anti-His-Tag antibody, Qiagen, Germany) were added after 2 min of acquisition. To stimulate neutrophils, PMA was added after 20 min. Acquisition was stopped after 40 min. The mean percentage change from baseline of the geometric mean fluorescence is presented. Baseline was determined by calculating the average FITC MFI during the period after addition of DARPins \((t = 2 \, \text{min})\) until stimulation with PMA \((t = 20 \, \text{min})\).

The gating strategies described above and the gating strategy for the identification of leukocyte subsets by flow cytometry in the murine experimental autoimmune myocarditis and cecal ligation and puncture model are described in the Online Resource 1.

Acquisition of all FACS data was performed using a BD FACS Canto II Flow Cytometer and FACS DIVA software. Data was analyzed with FACS DIVA V6.1 (Becton Dickinson, USA) and FlowJo© V10 software.

### Isolation of mouse cardiomyocytes

Isolation of murine cardiomyocytes was performed as described elsewhere [57]. Briefly, after removal, the murine heart was connected to a Langendorff perfusion system and perfused with collagenase containing buffers up to 50 min. After digestion, the heart was transferred into petri dishes, the atria were removed, and undigested parts of the heart muscle were eliminated using a filter. Isolated cardiomyocytes were then cultured in laminin-coated cell-culture dishes until used for experiments.

### Quantitative real-time PCR

Expression of Mac-1 in isolated monocytes and expression of ICAM-1 in isolated cardiomyocytes were assessed by quantitative real-time PCR (qRT-PCR). RNA from monocytes was isolated using the Aurum™ Total RNA Mini Kit (Bio-Rad, USA) within 30 min of isolation of primary mouse monocytes and after 24 h starvation of these monocytes (medium not supplemented with FCS). Cardiomyocyte-RNA was isolated within 30 min of cardiomyocyte isolation from whole murine hearts and after 4 h stimulation of these cardiomyocytes with mouse TNFα (10 ng/ml). Primers were obtained from Bio-Rad (Prime PCR™). QRT-PCR was performed according to standard protocols using SYBR Green (Bio-Rad, USA).

### Single-cell force spectroscopy of monocyte–cardiomyocyte interaction

To investigate whether F7 blocks the interaction of Mac-1 on monocytes with ICAM-1 expressed on cardiomyocytes, atomic force microscopy (AFM) based single-cell force spectroscopy (SCFS) was used, which is an established method to quantify cell–cell interaction forces [8, 34]. Monocytes were isolated from healthy C57BL/6N mice using a monocyte isolation kit (STEMCELL, France). Prior to SCFS mouse monocytes were stimulated with PMA (1 ng/ml, 15 min, 37 ºC) or PBS (negative control) and primary mouse monocytes were stimulated with mouse TNFα (10 ng/ml, 1 h, 37 ºC), incubated with either F7 or control DARPin (5 µg/ml, 15 min), attached to the cantilever of the AFM, and pressed onto cultured primary mouse cardiomyocytes. The detachment force \((F_{\text{det}} \, (\text{pN}))\) of monocytes attached to cardiomyocytes was recorded and used for statistical analysis.

### Mutagenesis analysis

Homology models were created of F7 and the mouse \(\alpha_m\) I-domain using SWISS-MODEL (http://swissmodel.expasy.org). The template for the mouse \(\alpha_m\) I-domain was the I-domain of human Mac-1 [5] and the template for F7 was the crystal structure of a DARPin in complex with AcrB [55]. The quality of the models was evaluated using the SWISS-MODEL Structure Assessment Tool (https://swissmodel.expasy.org/assess). The standard parameters of ZDOCK (http://zdock.umassmed.edu) were used to initially dock both models together. The top 10 DARPin F7: mouse \(\alpha_m\) I-domain complexes were analysed, with the lowest-energy complex of the largest docking cluster selected for more comprehensive docking using RosettaDock (Lyskov S., Gray J.J. “The RosettaDock server for local protein–protein docking” Nucleic Acids Research 36 (Web Server Issue), W233–W238 (2008)). The ten lowest-energy solutions were downloaded and visually analysed using the PyMOL Molecular Graphics System (Version 1.6.0.0, Schrodinger, USA). It was found that these ten solutions could be grouped into two clusters with very similar orientations. The lowest energy solutions of each cluster were visually analysed and led to two distinct models: “first model” and “second model”. Mutations in the mouse \(\alpha_m\) I-domain were conducted by “site-directed mutagenesis”. As the designated plasmids are usually very long, a proofreading polymerase (Phusion®, New England Biolabs, USA) was used. Due to repetitive sequences, mutations in DARPin F7 were created by cloning a DNA sequence containing the desired mutations (GeneArt™, Germany) into the expression vector. Successful mutagenesis was verified by sequencing. The location of the mutations within the DNA and protein sequences
of the mouse αM I-domain and DARPin F7 are presented in the Online Resources 2 and 3.

Binding of mutant F7 to mouse and human αM I-domains was assessed using ELISA. Wells were coated with 100 µl target antigen (0.1 µM, 4 h, 37 °C) per well (mouse αM I-domain wild type or mutants, human αM I-domain wild type), blocked with BSA (1%, 1.5 h, 37 °C), washed 6x with TBS-T, and incubated with 100 µl DARPin (F7 = 1 µg/ml if not otherwise specified, 1 h, 37 °C). After washing, Streptavidin-HRP (1:2000, 1 h, 37 °C; BD Biosciences, USA) followed by TMB substrate (50 µl/well) was added for visualisation.

Endotoxin removal

Prior to use, endotoxins were removed based on phase separation with Triton X-114 (Sigma-Aldrich, Germany) using standard protocols. Content of endotoxins was assessed using the LAL chromogenic endotoxin quantification kit (ThermoScientific, USA).

Intravital microscopy

To investigate the effect of DARPin on monocyte–endothelial interaction in vivo, a murine cremaster model of intravital microscopy was performed [4, 27]. Systemic inflammation was induced with 200 ng mouse TNFα i.p. (ThermoFisher Scientific, USA) in C57BL/6J mice (25–30 g) 3 h before surgery. For intravital microscopy, rhodamine dye was given intravenously and thereby circulating cells including leukocytes were made fluorescent and could be visually analyzed under the fluorescence microscope. Mice were anesthetized with ketamine (100 mg/kg) and xylazine (5 mg/kg) before 50 µl rhodamine 6G (0.1% solution with 0.9% NaCl) was applied and the cremaster model was performed. The skin was opened using fine scissors and connective tissue and fat was removed with the fine forceps freeing the cremaster muscle. The cremaster muscle was split using the vascular scissors, spread out and fixed using thread and tape. Care was taken to irrigate the operation site with sterile 0.9% NaCl followed by TMB substrate (50 µl/well) was added for visualisation.

Murine myocarditis model

To determine the anti-inflammatory potential of DARPin F7 in myocarditis, we used a well-established mouse model of experimental autoimmune myocarditis (EAM) as previously described [46]. 8-week-old female BALB/c mice (Charles River Laboratories, USA) received freshly mixed 0.1 ml porcine myosin (1 mg/ml) (Sigma-Aldrich, St. Louis, USA) subcutaneously on days 0 and 7. Mice were treated with F7, control DARPin, or PBS (Gibco, USA) i.p. (intraperitoneal route) on days 0, 7, 8, 9 in a saturating dosage (200 µg for DARPin, approximately 200 µl of a 1 mg/ml solution). Echocardiography was performed on days 0, 14 and 50. Blood samples were also collected on days 0, 14 and 50. The mice were euthanized on day 50 and histology was performed.

Echocardiography was performed under isoflurane anaesthesia (4 Vol%, AbbVie, USA) on a heating/ECG pad...
The heart rate was kept above 400/min. Loops were recorded with the VEVO 3100 micro-ultrasound imaging system (Fujifilm, Canada) and the left ventricular (LV) ejection fraction, stroke volume, cardiac output, left ventricular end-systolic volume (LVESV) and left ventricular end-diastolic volume (LVEDV) were measured in the parasternal long axis with Vevo lab software (Fujifilm, Canada).

After euthanasia and preparation of the heart, the atrium was punctured and mice were perfused with 10 ml of ice-cold saline solution, followed by perfusion with 4% paraformaldehyde (PFA) (Sigma-Aldrich, USA). The heart was removed and placed in 4% PFA for 1 h, followed by washing in PBS. The heart was then incubated for 4 h in 10%, 20% and 30% sucrose solution (Sigma-Aldrich, USA), respectively, followed by placement in optimal cutting temperature compound (OCT, Sakura Tissue Tek, The Netherlands) and cryosectioning. Histological analysis of murine hearts was performed with Masson's trichrome (fibrosis staining) and haematoxylin–eosin according to standard protocols. Immunohistochemistry was performed using an anti-CD68 monoclonal antibody (FA-11, 50 µl per slide, 1:500 dilution; 30 min, RT; Bio-Rad, USA) or an isotype control (Invitrogen, USA). Slides were then incubated with a secondary anti-rat-biotin-conjugated antibody (50 µl per slide, 1:200, 30 min, RT; Vector Labs, United Kingdom). The Vectastain® ABC Kit components (containing Avidin-HRP) were then added according to the manufacturer’s instructions (Vector Labs, United Kingdom). Images were acquired using an AxioImager M2 microscope and Zen Black 2.3 software (both: Zeiss, Germany) for image analysis.

Assessment of monocyte activation in ECMO and STEMI patients

Citrated whole blood was slowly drawn from an arterial line of patients receiving extra-corporeal membrane oxygenation (ECMO) and immediately transported to the laboratory for analysis. ECMO was initiated due to either respiratory or circulatory failure, the most common indications being acute respiratory distress syndrome or severe cardiogenic shock. Patients were aged over 18 years and had no haematological malignancies. Blood was taken 12 h to 7 days after ECMO implantation.

In a separate study, citrated whole blood was slowly drawn from patients diagnosed with ST-elevation myocardial infarction (STEMI) by antecubital vein puncture at a single time point within 36 h of percutaneous coronary intervention (PCI). Blood was immediately transferred to the laboratory. Only patients who had received coronary stents for coronary thrombosis and vessel occlusion as determined by coronary angiography were included. Patients with NSTEMI or unstable angina were not enrolled in this study. Patients with haematological malignancies or acute bacterial and viral infections were excluded.

Patient characteristics of ECMO and STEMI patients were taken from the electronic patient data management system and are presented in Online Resource 4 and 5. Citrated whole blood from healthy consenting volunteers with no known comorbidities or medication during the last 14 days was obtained for control experiments.

Using flow cytometry, binding of F7 to PMA-stimulated and unstimulated CD14+ monocytes from lysed whole blood was quantified using the appropriate controls. Whole blood was prepared as described for human samples under Flow-cytometric binding assays. Percentage of binding was calculated by dividing the mean fluorescence intensity of unstimulated samples by the MFI of PMA-stimulated samples, to account for lower stimulability in patients compared to healthy controls.

Study approval and registration

Experiments involving human or animal samples were approved by the institutional review board of the University of Freiburg, Germany, and the Alfred Hospital, Melbourne, Australia. Participants or their legal representatives (in the case of ECMO patients) gave written informed consent in accordance with the Declaration of Helsinki. The cross-sectional observational studies were registered in the German Clinical Trials Register: DRKS00005277 (STEMI-patients), DRKS00011106 (ECMO patients).

Statistics

Data are presented as mean ± SEM and analysed using two-tailed Student’s t-test when two groups were compared or one-way ANOVA with a Tukey post-hoc test when three or more groups were compared. Experiments were performed at least three times and were measurements from distinct biological replicates unless stated otherwise. Statistics were performed using GraphPad Prism 8.0 software (GraphPad, USA). p < 0.05 was considered statistically significant.

Results

Biological activity of recombinant mouse I-domain

Panning was performed on the recombinant mouse αM I-domain, which has a sequence identity of 80% with the human αM I-domain (according to protein sequence alignment by https://blast.ncbi.nlm.nih.gov/ based on the Swissprot library). The rationale was to select a DARPin which
could be tested in mouse preclinical models. There was a high likelihood of selecting a DARPin which would display cross-reactivity to the human αM I-domain due to the large sequence identity. To demonstrate that the recombinantly produced mouse I-domain, which is used as a target epitope for phage display, is biologically active, murine ICAM-1 was coated on 96-well plates. Recombinant mouse αM I-domain binds to murine ICAM-1 in comparison to BSA-coated wells (Fig. 1b).

**Anti-αM I-domain phage panning**

After three panning rounds on recombinant mouse αM I-domain, specific enrichment of anti-αM I-domain DARPin phages was found (Fig. 1c). DARPin-encoding plasmid inserts were cloned into the expression vector pMPAG-6 and several hundred DARPin clones were screened for their binding to the αM I-domain. Of these DARPin clones, the clone F7 (= “DARPin F7”) was found to bind most specifically to the recombinant αM I-domain (Fig. 1d). Homology analysis of selected clones showed that three different “families” of anti-mId DARPin clones were selected within the three panning rounds, indicating a highly efficient panning strategy (Online Resource 6).

**Expression and purification of DARPins in E. coli and endotoxin removal**

DARPins were successfully expressed and purified with high yields (concentration of DARPins was up to 5 mg/ml) (Fig. 1e). Before endotoxin elimination, DARPin samples contained approximately 3 EU/ml (endotoxin unit/ml, 1 EU/ml corresponds to 0.1 ng endotoxin per ml). After endotoxin-removal (see “Methods” section), endotoxin concentration was below 0.1 EU/ml.

**Binding of DARPin F7 to mouse αM I-domain and mouse monocytes**

F7 showed concentration-dependent specific binding to recombinant mouse αM I-domain (Fig. 2a). Phorbol 12-myristate 13-acetate (PMA) was used to activate monocytes resulting in increased activation of Mac-1 [25]. F7 bound significantly stronger to PMA-stimulated (immortalized) mouse monocytes (RAW 264.7) (Fig. 2b). Specific binding of F7 in comparison to a control DARPin (DARPin E3_5) [32] to activated monocytes was confirmed for Ly-6C++ mouse blood monocytes (Fig. 2c).

**DARPin F7 reduces monocyte–ICAM-1 interaction in flow cytometry**

The capacity to block ICAM-1–Mac-1 interaction was demonstrated by flow cytometry (Fig. 2d). Pre-incubation of mouse monocytes with F7 led to significantly reduced binding of recombinant ICAM-1 compared to treatment with the control DARPin or PBS.

**Docking model and mutational analysis of DARPin F7 and mouse αM I-domain**

Homology modelling and computational docking were performed to identify the interaction sites between F7 and the mouse αM I-domain. Two potential protein–protein models were generated. In both models, three F7 residues (E46, D71, D79) were predicted to be important for the interaction with the mouse αM I-domain. In the first model (not shown), the F7 side chain E46 was predicted to hydrogen-bond with the side chain of the mouse αM I-domain N206, D71 with the side chain of the mouse αM I-domain N146, and D79 with the backbone of mouse αM I-domain I148. There was also a predicted salt bridge between the side-chains of F7 R13 and the mouse αM I-domain E179. In the second model, mouse αM I-domain R208 was predicted to be involved in a bifurcated salt bridge and hydrogen-bond network with F7 D71 and D79 (Fig. 3a). Mouse αM I-domain F246 was predicted to be involved in hydrophobic interactions with F7 F36, I68, and L69 (Fig. 3a). To biologically assess these models, mutagenesis of F7 and mouse αM I-domain was conducted and their ability to still interact was assessed.

An alanine triple mutant of F7 (E46A_D71A_D79A = mutated DARPin, mF7) was created and did not bind to the mouse αM I-domain (Fig. 3b). Furthermore, the mutated DARPin showed significantly reduced binding to activated mouse monocytes compared to F7 in mouse Ly-6C++ monocytes (Fig. 3c).

For the mouse αM I-domain, the following mId-mutants were created and assessed: N146A_E179A_N206A, R208A, F246D, R208A_F246D, N146A, E179A, N206A. The N146A_E179A_N206A did not result in loss of binding to F7 (data not shown); however, the double mutation R208A_F246D of the mouse αM I-domain did not show significant binding to F7 (Fig. 3d), whereas the mouse αM I-domain single mutations (R208A, F246D) alone were not able to alter the binding affinity to F7 (Fig. 3d). In summary these data support the second model as depicted in Fig. 3a.

An overview of mutation sites located within the sequences of DARPin F7 or the mouse αM I-domain are presented in Online Resource 2 and 3.
Fig. 2 Characterizing DARPin F7. a Increasing concentrations of F7 led to increased signals at OD 450 nm in ELISA, indicating concentration-dependent binding behaviour. The x-axis shows increasing concentrations of DARPin F7. Controls are also shown. Wells were incubated overnight at 4 °C with recombinant mouse α MI-domain. As negative controls, PBS and the control DARPin were used. F7 binding was detected via Streptavidin HRP using OD measurements at 450 nm (n = 3, ***p < 0.001). p-values were calculated by one-way ANOVA. b RAW 264.7 cells were cultured according to standard protocols. 5 × 10⁵ cells were resuspended in 100 µl PBS + Ca²⁺ and Mg²⁺ and stimulated with phorbol 12-myristate 13-acetate (PMA). PMA was added to stimulate cells and induce Mac-1 conformational change towards the activated conformation on the cellular surface. Cells were then stained with DARPin (F₇ = 2.5 µg/ml). RAW 264.7 cells were identified based on scatter gating and their CD11b expression using a FITC anti-CD11b antibody. DARPin binding was detected using an Alexa Fluor 488 anti-His-tag antibody. Flow-cytometric analysis showed that F7 bound significantly stronger to PMA-simulated “+” compared to unstimulated “−” RAW 264.7 cells (n = 4, *p < 0.05). p-value was calculated by an unpaired two-tailed Student's t-test. c 100 µl of mouse blood was stimulated with PMA (F₇ = 200 ng/ml, 15 min, 37 °C) followed by red blood cell lysis. PMA was added to stimulate monocytes and induce Mac-1 conformational change towards the activated conformation on the monocyte surface. Cells were stained with a Pacific Blue anti-Ly-6C antibody and DARPin (F₇ = 2.5 µg/ml). Binding of DARPin F7 to Ly-6C⁺⁺ monocytes (defined as the top 3% percent of Ly-6C positive cells) is shown. Location of the monocytes in the monocyte gate was verified by backgating. DARPin binding was detected using an Alexa Fluor 488 anti-His-tag antibody. For more information, please see our gating strategy (Online Resource 1). No relevant binding of F7 to unstimulated “−” Ly-6C⁺⁺ mouse blood monocytes was found. However, F7 bound significantly more to PMA-stimulated “+” monocytes. The control DARPin did not bind significantly to non-activated or activated Ly-6C⁺⁺ mouse blood monocytes was found. However, F7 bound significantly more to PMA-stimulated “+” monocytes. The control DARPin did not bind significantly to non-activated or activated Ly-6C⁺⁺ mouse monocytes (n = 4, ***p < 0.001). d Monocytes were isolated from healthy C57BL/6N mice using a monocyte isolation kit (STEMCELL, France), stimulated with PMA (10 ng/ml, 15 min, 37 °C) and stained with DARPin (5 µg/ml, 15 min, RT) followed by incubation with rICAM (15 min, RT). ICAM-1-binding was detected by a FITC anti-ICAM-1 antibody (Biolegend, USA). Isolated monocytes were identified by forward vs side scatter gating. Competitive binding of F7 vs fluorescent recombinant ICAM-1 (rICAM) revealed that F7 significantly reduced binding of ICAM-1 to primary mouse monocytes (n = 3, *p < 0.05). p-values were calculated by one-way ANOVA. The error bars indicate SEM.
It has been postulated that the αM I-domain itself undergoes significant conformational changes upon integrin activation beyond the exposure of the I-domain as a consequence of Mac-1 activation. The active conformation can be induced by the F302L mutation, creating a constitutively activated mouse αM I-domain [36]. Binding of F7, mF7, and the control DARPin to mId_F302L was similar to the wild-type mId, indicating that the epitope within the αM I-domain to which F7 binds is not affected by conformational changes in the αM I-domain (Fig. 3e).

**Fig. 3** Defining specific interaction residues of DARPin F7 to mouse αM I-domain using homology modelling and docking studies. (a) Model of F7 (magenta) interacting with the mouse αM I-domain (green). Shown via magenta sticks are the three F7 residues (E46, D71, D79) proposed to be important for binding via polar interactions and the three F7 residues (F36, I68, L69) proposed to be involved in hydrophobic interactions. Shown via green sticks are the two mouse αM I-domain residues (R208, F246) proposed to be important for binding. Also shown via yellow dashed lines are the putative hydrogen bonds. (b) Wells were coated with mouse αM I-domain and biotinylated DAR Pins (F₇ = 1 µg/ml) were added. After several washing steps, Streptavidin-HRP was added, followed by TMB-substrate and the OD₄₅₀nm was quantified in an ELISA plate reader. The F7 alanine triple mutant (E46A_D71A_D79A, “mutated DARPin”) bound significantly less to the mouse αM I-domain compared to F7. (n=3, *** p < 0.001). e 100 µl of mouse blood was stimulated with PMA (F₇ = 200 ng/ml, 15 min, 37 °C) followed by red blood cell lysis. PMA was added to activate monocytes and induce Mac-1 conformational change towards the activated conformation on the monocyte surface. Cells were stained with a Pacific Blue anti-Ly-6C antibody and DAR Pins. Binding of DARPin F7 to Ly-6C⁺⁺ monocytes (defined as the top 3% percent of Ly-6C positive cells) is shown. Location of the monocytes in the monocyte gate was verified by backgating. DARPin binding was detected using an Alexa Fluor 488 anti-His-tag antibody. Flow-cytometric analysis showed that F7 bound significantly more strongly to PMA-stimulated “+” compared to unstimulated “−” mouse monocytes. Also, F7 bound significantly more to stimulated mouse monocytes compared to mutated and control DARPin. This indicates that the residues (E46, D71, D79) contribute to F7 binding to mouse Ly-6C⁺⁺ monocytes. There is a small degree of unspecific background binding of the mutant DARPin in our flow cytometric whole blood assay (n=4, ***, p < 0.001). d For this ELISA, wells were coated with mouse αM I-domain or mouse αM I-domain mutants and biotinylated DAR Pins (F₇ = 1 µg/ml) were added. After several washing steps, Streptavidin-HRP was added, followed by TMB-substrate and the OD₄₅₀nm was quantified in an ELISA plate reader. Binding of F7 to the mouse αM I-domain double mutant F246D_R208A was significantly reduced compared to the mouse αM I-domain wild type (n=3, *** p < 0.005). F246 and R208 therefore most likely constitute the epitope of F7 on the mouse αM I-domain. e ELISA was performed as described in d. Binding of F7 was not affected by the conformational shift induced by the activating F302L mutation in the mouse αM I-domain (n=3, ** p < 0.05). p-values were calculated by one-way ANOVA. The error bars indicate SEM.
To investigate the in vivo effects of F7 on leukocyte function, we conducted intravital microscopy using the cremaster mouse model. We were able to show that mice treated with F7 had reduced numbers of adherent leukocytes visualized by fluorescence microscopy using rhodamine staining (Fig. 4a–e). Furthermore, the rolling velocity of leukocytes in mice treated with F7 was significantly increased, indicating an inhibitory effect of F7 on Mac-1 function in vivo (Fig. 4f).

**Anti-inflammatory effect of DARPin F7 in CLP model**

Inhibition of leukocyte migration by activation-specific Mac-1 blocking was further assessed in a mouse sepsis CLP model. Mice treated with either F7 or the control DARPin had similar total leukocyte counts in blood or peritoneal lavage (Fig. 4g) as determined by automated cell counting. Using flow cytometry, we found similar levels of neutrophils in blood in mice treated with F7 or the control DARPin. However, significantly reduced levels of neutrophils were counted in the peritoneal lavage (Fig. 4h,i). Moreover, mice treated with F7 had significantly reduced numbers of total and inflammatory monocytes in the peritoneal lavage (Fig. 4m–n). Additionally, we determined cytokine levels in blood and the peritoneal lavage from mice in both groups and found similar levels in both treatment groups (Online Resource 7). No differences in weight loss or survival between the different treatment groups were observed in the 20 h monitoring period after surgery until euthanasia.

**DARPin F7 prevents loss of left ventricular function in murine myocarditis**

Myocarditis is an inflammatory cardiomyopathy that appears in approximately 1.5 million people worldwide annually [29]. Overshooting inflammatory reactions are seen as a major cause of myocardial damage in myocarditis [64]. Expression of ICAM-1 by cardiomyocytes could mediate interaction with monocytes expressing Mac-1, leading to potential cardiomyocyte dysfunction. We, therefore, investigated ICAM-1 expression in mouse cardiomyocytes and Mac-1 expression in mouse monocytes by qPCR, confirming significant expression of Mac-1 in isolated mouse monocytes and expression of ICAM-1 in mouse cardiomyocytes (relative mRNA expression of Mac-1: monocytes unstimulated vs stimulated: 1.00 ± 0.30 vs 2.38 ± 0.45; n = 5, p < 0.05; relative mRNA expression of ICAM-1 on mouse cardiomyocytes unstimulated vs stimulated: 1.00 ± 0.42 vs 2.84 ± 0.59, n = 5, p < 0.05, Online Resource 8). Endothelial cells, however, also highly express ICAM-1 [44].

To investigate whether monocytes attach to cardiomyocytes in an σM I-domain-dependent manner with subsequent cardiomyocyte dysfunction, atomic force microscopy (AFM) based single-cell force spectroscopy (SCFS) was performed (Fig. 5a). The force necessary to detach stimulated mouse monocytes which had been pre-incubated with F7 from mouse cardiomyocytes was...
Leaf spring

Monocyte

Cardiomyocytes

ICAM-1

MAC-1

Stimulated monocytes

Control DARPin

PBS

Control DARPin

Positive control

Negative control

CD68

macrophages per mm²

Day 50

LVEF [%]

Cardiac output [ml/min]

Stroke volume [µl]

LVEDV [µl]

LVESV [µl]

ns

ns

ns

***

***

***

***

***

***

***

***

***

***

***

***

***

***

***

***

***
ogy was performed. The number of macrophages (CD68+) (Online Resource 9). At day 50 after euthanasia, histol 
hearts indicating a successful induction of myocarditis 14 was observed using flow cytometry of lysed mouse 
of monocytes and neutrophils into the myocardium on day 50. A significant influx of monocytes and neutrophils was induced in the myocardium by inhibition of monocyte–cardiomyocyte interaction. We then assessed the interaction of monocytes with cardiomyocytes pre-incubated with F7 compared to the control DARPin and PBS (n = 10 mice per treatment group, ***p < 0.001). 

Immunohistochemistry was performed using an anti-CD68 monoclonal antibody (FA-11) or an isotype control followed by incubation with a secondary anti-rabbit-conjugated antibody. The Vectastain® ABC Kit components (containing Avidin-HRP) were then added according to the manufacturer’s instructions. Images were acquired using an AxiosImager M2 microscope and analysed using Zen Black 2.3 software. Significantly reduced numbers of macrophages (brown colour) were found for mice treated with F7 compared to treatment with the control DARPin and PBS (n = 9 mice per treatment group, ***p < 0.001). p-values were calculated by one-way ANOVA. Scale bar = 50 µm. 

Echocardiography was performed under isoflurane anesthesia on a heating/ECG pad. The heart rate was kept above 400/min. The left ventricular (LV) ejection fraction was measured in the parasternal long axis. Echocardiography revealed that mice treated with F7 did not suffer significant reduction in left ventricular ejection fraction (LVEF) on day 14 and day 30 compared to mice treated with the control DARPin or PBS in a murine model of myocarditis. Similar observations were made regarding cardiac output (f) and stroke volume (g). No differences between treatment groups were observed regarding cardiac output (f) and stroke volume (g). No differences between treatment groups were found regarding cardiac output (f) and stroke volume (g) and chronic phase of myocarditis, these parameters differed significantly between the treatment groups and were best in the F7 group (Fig. 5e–g). Left ventricular enddiastolic volume (LVEDV) and left ventricular endystolic volume (LVESV) showed no significant differences between treatment groups (Fig. 5h, i). Examples of echocardiographic loops on day 14 from representative mice are provided as Online Resources 13–15.

DARPin F7 reduces inflammation in myocardial infarction

An overshooting inflammatory reaction is one of the major drivers of ischaemia/reperfusion (I/R) injury after myocardial infarction [35] and anti-inflammatory therapy has been shown to preserve cardiac function [84]. Targeting activated Mac-1 may, therefore, be a novel therapeutic option to possibly reduce overshooting inflammation causing cardiac ischaemia/reperfusion injury. Using a mouse model of cardiac ischaemia/reperfusion injury (30 min LAD ligation), we found significantly reduced levels of CD68+ macrophages and CD8+ cells in the myocardium of mice treated with F7 compared to the control DARPin. Furthermore, a reduced infarct size was observed histologically in mice treated with F7 (Online Resource 16).

Translation of DARPin F7 binding to human leukocytes

To provide proof of the translational relevance of our findings and ultimately the suitability of F7 for diagnostic and therapeutic applications in humans, we systematically tested F7 targeting human Mac-1. To ensure the functionality of our tools, we first demonstrated that the recombinant
Fig. 6  Translation of DARPin F7 to human applications. a In this ELISA, wells were coated with recombinant human ICAM-1. The recombinant human αM I-domain or BSA was added to the wells and binding was detected by an anti-His-HRP antibody and quantified at OD450nm in an ELISA plate reader. It was found that recombinant ICAM-1 bound significantly more to human αM I-domain than to the control (BSA) indicating functionality of the human αM I-domain (n = 3, ***p < 0.001). p-value was calculated by an unpaired two-tailed Student’s t-test. b For this ELISA, wells were coated with the recombinant human αM I-domain and biotinylated DARPin were added (Fe = 1 µg/ml). DARPin binding was detected by a Streptavidin-HRP antibody and quantified at OD450nm. DARPin F7 bound significantly more to the immobilized human αM I-domain compared to the control DARPin or the mutated DARPin in ELISA (n = 3, ***p < 0.001). c Human whole blood monocytes were stimulated with PMA (stimulated, “+”) or PBS (unstimulated, “-”). PMA was added to activate cells and induce Mac-1 conformational change on the monocyte surface. Staining and gating for classical monocytes (CD14+) was performed as described in Online Resource 1. DARPin binding was detected by a secondary Alexa Fluor 488 anti-His-tag antibody. F7 bound significantly more to stimulated “+” human CD14+ monocytes compared to unstimulated “-” monocytes. F7 also bound stronger to stimulated “+” monocytes than the mutated DARPin and the control DARPin. There is a small degree of unspecific background binding of the mutant DARPin in our flow cytometric whole blood assay (n = 14, ***p < 0.001, p-values were calculated by one-way ANOVA). d The same flow cytometric assay as in c was carried out. The detection of the population shift occurring after CD14+ monocyte stimulation with PMA was compared between DARPin F7 (2.5 µg/ml) and other anti-Mac-1 antibodies M1/70, Mab24, MAN-1, Mab107, CBRM1/5, and 2LP19c (all 10 µg/ml). Visual analysis shows a larger population shift detected by DARPin F7 compared to the other anti-Mac-1 antibodies. It was concluded that due to this capacity, F7 binds conformation-specifically to activated Mac-1 on PMA-stimulated, activated human monocytes (representative histograms of n = 3). e The flow cytometric assay was conducted as described for Fig. 3c. However, before the addition of DARPin, stimulated “+” human whole blood monocytes were pre-incubated with anti-CD11b antibodies Mab107 and M1/70. F7 binding to activated monocytes was reduced by competition with anti-CD11b antibodies M1/70 and Mab107 at 50 µg/ml (n = 3, ***p < 0.001, **p < 0.01, p-values were calculated by one-way ANOVA). According to our in-silico model Mab107 binding sterically mirrors binding of F7 to the αM I-domain. p-values were calculated by one-way ANOVA. f Neutrophils were isolated from whole human blood using PolymorphPrep®. 5 x 10⁶ neutrophils were stained with a Pacific Blue anti-CD66b antibody for identification. After 2 min of acquisition and recording, F7 or the control DARPin and the secondary Alexa Fluor 488 anti-His-Tag antibody were added. Recording was continued for a total of 20 min when PMA was added to stimulate neutrophils and induce Mac-1 conformational change towards the activated conformation on the neutrophil surface. Recording was continued for another 20 min and binding was detected in the FITC channel and is presented as percentage change from baseline since baseline binding between F7 and the control DARPin were different. F7 also bound significantly more to PMA-stimulated neutrophils compared to the control DARPin (n = 3, **p < 0.01 at 35 min, F7 vs control DARPin). p-value was calculated by an unpaired two-tailed Student’s t-test. g Observation of CXC receptors were conducted to evaluate the capacity of F7 to detect monocyte activation in patients. Citrated blood was drawn from ECMO or STEMI patients and F7 binding to CD14+ monocytes was determined by flow cytometry as previously described in e and in the “Methods” section. F7 bound significantly more to CD14+ monocytes of ECMO and STEMI patients than to healthy controls, indicating increased monocyte activation in these patients (ECMO n = 16 patients, STEMI n = 17 patients, healthy controls n = 16, *p < 0.05). p-values were calculated by one-way ANOVA. The error bars indicate SEM.
Discussion

The aim of the present study was to select and test DARPin s that preferentially bind to the activated conformation of the leukocyte integrin Mac-1 in order to obtain, first, a diagnostic tool for the assessment of monocyte activation and, second, a therapeutic anti-inflammatory agent selectively targeting activated monocytes.

By choosing the $\alpha_M$ I-domain of murine Mac-1, which shares a high sequence homology with the $\alpha_M$ I-domain of human Mac-1, as a target for our DARPin selection, we generated and selected a DARPin that binds to mouse and human Mac-1. This cross-reactivity provided the opportunity to test the selected DARPin in therapeutic approaches in preclinical mouse disease models and thus to greatly facilitate a future drug development programme in humans.

Different strategies have been employed to generate activation-specific antibodies to Mac-1. Diamond et al. selected immunoglobulins from hybridoma supernatants for their ability to bind PMA-activated neutrophils, while Eisenhardt et al. employed a subtractive panning strategy using human scFv phage libraries on Mac-1-expressing CHO cells [20, 24]. Both were cell-based selection strategies, whereas our approach is based on the use of immobilized recombinant mouse $\alpha_M$ I-domain to select activation-specific binders from a DARPin phage library (Fig. 1). Our strategy is supported by the fact that the epitopes of MAN-1 and CBRM1/5 are also located on the $\alpha_M$ I-domain of Mac-1 [12, 21]. It, therefore, resembles physiological ligand binding to the activated receptor conformation [6]. Competitive orthosteric activation-specific blocking of Mac-1 by F7, which prevents ligand interaction, may offer several advantages over an allosteric binding mode, which can induce an activated, pro-adhesive state of the integrin with severe immune activation and reduced outcomes [3].

The selected anti $\alpha_M$ I-domain DARPin F7 has significant advantages in comparison to immunoglobulins: it is relatively small (~17 kD) and thus can penetrate more easily into tissue, it is highly thermo- and pH-stable, is less likely to induce allergic reactions, and can be easily produced in bacteria at large scales [42]. F7 showed dose-dependent binding to the mouse $\alpha_M$ I-domain and specific binding behaviour to PMA-activated mouse monocytes compared to the control DARPin. Additionally, ICAM-1, which also binds to activated Mac-1 via the I-domain, was inhibited by F7, indicating competitive, specific binding of F7 [22].

To further characterize the binding of F7 to the $\alpha_M$ I-domain, a mutational analysis of F7 was conducted. We determined that the paratope on F7 is comprised of the residues E46, D71, and D79, since the F7 alanine triple mutant failed to bind to the human or mouse Mac-1 $\alpha_M$ I-domains and displayed significantly reduced binding to activated human and mouse monocytes. These residues are located on the antigen-binding surface of F7. Interestingly, according to our in silico models, these loops sterically mirror the loops of the heavy chain of mAb107 when binding to the human $\alpha_M$ I-domain [52]. In support of this, we could demonstrate that in a competitive manner, mAb107 is able to significantly reduce the binding of F7 to human monocytes in flow cytometry. These data further endorse our proposed model of interaction between F7 and the $\alpha_M$ I-domain.

Our proposed model of binding may well be an established form of the $\alpha_M$ I-domain interacting with ligands [52]. It was demonstrated that R208 and F246 of the mouse $\alpha_M$ I-domain constitute the binding epitope for F7, resulting in less binding of F7 to the $\alpha_M$ I-domain with mutations of these residues. Interestingly, these two residues are conserved in the human $\alpha_M$ I-domain, offering an explanation for the specific binding of F7 to the human $\alpha_M$ I-domain and human monocytes. Additionally, other Mac-1 ligands bind to the same residues on the $\alpha_M$ I-domain. Among these, R208 is known to mediate binding to NIF (neutrophil inhibitory factor). Both R208 and F246 are required for binding to IC3b [62]. Furthermore, an epitope which is composed of residues located relatively far apart on the primary structure is characteristic of and in line with the mosaic model of Mac-1 proposed by Ustinov et al. [76]. Binding of F7 to the mouse $\alpha_M$ I-domain was also shown to occur independent of the I-domain’s conformational status. These binding characteristics can be explained by the fact that R208 and F246, the epitope for F7 on the mouse $\alpha_M$ I-domain, are not subject to conformational change upon I-domain activation [52].

Our hypothesis of activation-specific binding to activated Mac-1 is empirically further supported by increased binding of F7 to PMA-stimulated monocytes compared to other anti-Mac-1 antibodies including mAb107, which has a similar epitope, and CBRM1/5, an antibody claimed to bind specifically to activated Mac-1 [21, 52]. Various conformationally sensitive DARPin s have been selected against different receptors, demonstrating the particular suitability of the DARPin technology for targeting specific conformations in target epitopes, and thus the increased affinity of F7 for activated Mac-1 on monocytes may be favoured by inherent properties of DARPins such as sterical advantages or smaller size [54]. In summary, F7 binds specifically to the activated receptor conformation of the leukocyte integrin Mac-1 and may serve as a diagnostic tool indicating monocyte activation status.

One of the initial steps in inflammation is leukocyte rolling, adhesion to endothelial cells and transmigration into the subendothelial space [28]. Several studies have found that the leukocyte integrin Mac-1 is particularly involved in slow rolling, firm adhesion, and intravascular crawling of leukocytes [23, 71]. To investigate the therapeutic blocking effect of F7 on leukocyte–endothelial interaction, intravital
microscopy using a cremaster mouse model was performed [80]. Our data are in line with the reported role of Mac-1, as we found that F7 significantly increases rolling velocity and inhibits adherence of activated leukocytes on the vascular endothelium. These data indicate that F7 effectively inhibits leukocyte–endothelial interaction and thereby the early stage of (vascular) inflammation. This led us to explore the therapeutic anti-inflammatory effects of F7 in mouse models of inflammatory diseases.

Sepsis and septic shock are serious conditions associated with overshooting inflammation and high mortality. Treating the overshooting inflammation in sepsis using immunomodulatory therapies in the clinical setting has proven to be difficult [14], possibly due to the use of unspecific anti-inflammatory strategies. Targeting specifically and only activated Mac-1 on monocytes and neutrophils is an innovative approach that could lead to an effective agent for the management of overshooting inflammation in sepsis and septic shock. The mouse model of cecal ligation and sepsis is a well-established model for the study of severe sepsis and was chosen to determine whether F7 inhibits monocyte and neutrophil migration into areas of inflammation [63]. Neutrophils and monocytes (total monocytes and inflammatory monocytes) in peritoneal lavage were significantly reduced in animals that received F7. Monocyte count in blood, however, was not significantly different for mice treated with F7 or the control, indicating that F7 might have avoided monocyte migration into the peritoneal lavage.

Myocarditis is one of the leading causes of sudden cardiac death and cardiac transplantation [17]. Although myocarditis is believed to be a T-cell driven disease, the pathological effects and myocardial damage are often mediated by effector cells; particularly monocytes [77]. After infection with cardiotropic viruses or exposure to cardiotoxic substances, cardiomyocytes undergo necrosis and cell lysis, with subsequent infiltration of lymphocytes and monocytes into the cardiac tissue, finally resulting in an autoimmune reaction with impaired cardiac function and heart failure [16]. However, to this date there is no established targeted anti-inflammatory therapy available and management focuses on managing the complications of myocarditis [13, 65]. Due to the strong involvement of monocytes/macrophages in myocarditis [1], targeting activated Mac-1 is an attractive therapeutic approach. We investigated whether F7 is a potential, sought-after, novel anti-inflammatory drug for the treatment of myocarditis. The results obtained with F7 are striking. Loss of LV function could be prevented. Furthermore, we showed that the recruitment of monocytes/macrophages was reduced significantly. Most interestingly, using AFM based SCFS we could show that inhibition of activated Mac-1 by F7 reduces the adhesion of activated monocytes to murine cardiomyocytes. This provides a new aspect of the pathology of myocarditis and also suggests a new path of therapeutic intervention.

Our findings are in line with those of Kolattukudy et al., who found that migration of monocytes into cardiac tissue resulted in myocarditis with depressed contractile function [43]. The importance of macrophage accumulation in the cardiac tissue on prognosis in myocarditis patients was investigated by Kindermann and colleagues [41]. By analysing human endomyocardial biopsies, they found that immunohistological signs of inflammation such as CD68-positive cells, but not the abundance of cardiotropic viruses, predicted the outcome of patients with myocarditis. Hence, prophylactic inhibition of monocyte/macrophage accumulation into the cardiac tissue, as performed in the present study by targeting the activated conformation of Mac-1, represents a promising therapeutic approach for the treatment of myocarditis patients.

These data demonstrating the therapeutic potential of F7 can also serve as a model for the treatment of other inflammatory conditions. These include arthritis [74], glomerulonephritis [73], bullous pemphigoid [47], experimental autoimmune encephalopathy [30], inflammatory bowel disease [58], and ischaemic kidney injury [19].

Targeting Mac-1 may also carry risks. Mac-1 deficiency is associated with an increased susceptibility to bacterial infection due to an impeded neutrophil response [61]. Although an unspecific Mac-1 blockade might, therefore, in theory, also predispose towards infection, we argue that the risk can be significantly reduced by specifically targeting only the activated receptor conformation (as with F7) leaving the functions of the non-activated Mac-1 receptor intact. In the various mouse models performed, mice that received F7 showed no signs of infection and did not develop weight loss compared to controls indicating that blocking-activated Mac-1 is well tolerated.

We demonstrated that F7 binds specifically to the human αM I-domain of Mac-1 and to activated human monocytes and neutrophils and as such represents an interesting diagnostic tool. To assess the suitability of DARPin F7 for the measurement of monocyte activation in the clinic, we investigated patients in whom identification of inflammatory reaction could be helpful. Current markers of inflammation (CRP, white blood cell count etc.) are nonspecific and increases are often observed too late, after severe inflammation has already set in. As opposed to CRP, Mac-1 conformational change occurs within <1 s of monocyte activation [72] and could serve as a rapid marker of inflammation, enabling the identification of patients at risk. Elevated levels of inflammation, as determined by CRP, have been associated with poor outcomes after myocardial infarction [11], but a rise in CRP levels after myocardial infarction is usually delayed, peaking after 50 h [18].
We, however, have demonstrated increased monocyte activation as determined by increased binding of F7 to monocytes in STEMI patients within 36 h of PCI. Our results are in line with data from other groups which have detected increased monocyte activation after myocardial infarction by different means [66].

Furthermore, in addition to the ability to identify monocyte activation after myocardial infarction, F7 as a therapeutic agent may also be able to reduce inflammation contributing to cardiac ischaemia/reperfusion injury as shown in a mouse model of LAD ligation and reperfusion. The multifactorial harmful processes developing after reperfusion of the myocardium have been difficult to target therapeutically [33, 35, 37]. Our data are in line with previous studies which found anti-inflammatory strategies hold promise towards reducing ischaemia–reperfusion injury [51, 84]. Targeting activated Mac-1 on monocytes and neutrophils may, therefore, expand the anti-inflammatory therapeutic options for the prevention of cardiac ischaemia/reperfusion injury.

A patient cohort associated with the potential risk of severe inflammatory reactions are patients on ECMO, an extracorporeal circulatory support system that is increasingly used as a last resort for patients with respiratory and/or circulatory failure. Increased monocyte activation has been described in these patients [31]. Moreover, ECMO itself can trigger inflammatory reactions, which is independent of the underlying medical condition and is associated with worse outcome [53]. This ECMO-induced systemic inflammatory response syndrome is initiated by complementary activation upon blood contact with foreign surfaces, which later leads to leukocyte activation [53]. Increased Mac-1 expression on leukocytes has been reported in ECMO patients and could serve as a method for rapid assessment of immune activation in these patients [26]. We showed increased binding of F7 to activated monocytes in ECMO patients as compared to healthy controls.

F7 was also able to detect activated Mac-1 on monocytes in patients with pulmonary sepsis where early detection is crucial for survival. Previously, Eisenhardt et al. showed that the activation-specific anti-Mac-1 single-chain antibody MAN-1 could identify septic patients in the intensive care unit through its binding to activated monocytes [25]. In another cohort, MAN-1 was able to detect a reduction in monocyte activation after renal denervation in severely hypertensive patients [83]. CBRM1/5, on the other hand, only recognizes a subset of activated leukocytes [21], which does not support its application as a diagnostic tool.

A central disadvantage of MAN-1 and CBRM1/5 is, however, that they do not show binding to mouse Mac-1, which prevents testing of these antibodies as potential anti-inflammatory drugs in classical murine models of disease. F7, on the other hand, demonstrates binding to both mouse and human Mac-1, allowing broad and thorough testing for diagnostic and therapeutic use in mouse models. As in vivo testing in animal models is a prerequisite, especially for drug development, F7 is well placed for a drug-development program.

Moreover, F7 can be used to detect leukocyte activation in multiple inflammatory conditions. For instance, it was reported that Mac-1 expression correlates with disease activity in granulomatosis with polyangiitis [56]. Mac-1 expression was also increased on monocytes in patients with rheumatoid arthritis [45], in patients after percutaneous coronary intervention who developed restenosis [38] and in patients with sickle-cell disease [39].

DARPins offer several advantages over immunoglobulins, which were mentioned earlier. Potential disadvantages should also be considered, particularly the issue of immunogenicity. DARPins could potentially cause allergic reactions in humans as they present foreign antigens. Recent phase II clinical trials have, however, reported safe systemic application, e.g. the drug candidate MP0250, an anti-VEGF/HGF DARPin for the treatment of multiple myeloma [70]. Moreover, mice receiving DARPins in our preclinical models did not show any symptoms of allergic reactions or die prematurely. Additionally, like immunoglobulins, DARPins share the potential disadvantage of being protein therapeutics, which requires parenteral application. However, antibody or similar drugs are for some time now attracting the majority of pharmaceutical research investment and subcutaneous applications with weekly or even monthly injection intervals appear particularly attractive [48].

In conclusion, we were able to select a DARPin, which selectively binds and blocks the I-domain of Mac-1 and thereby specifically identifies and inhibits activated monocytes and neutrophils, both in mice and in humans. DARPin F7 shows highly promising therapeutic effects in mouse models of inflammation and can detect monocyte activation in patients.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s00395-021-00849-9.

**Acknowledgment** We acknowledge the support of Molecular Partners for supplying us with a DARPin phage library and we also acknowledge the support of Daniel Steiner, who is an employee of Molecular Partners, in advising on the use of this DARPin phage library. Funding from the Victorian Government Operational Infrastructure Support Scheme to the Baker Heart and Diabetes Institute and St. Vincent’s Medical Research Institute is acknowledged.

**Author contributions** P.M.S.: study design, acquisition, analysis and interpretation of data, preparation of manuscript. I.B.: study design, acquisition, analysis and interpretation of data, preparation of manuscript. N.B.: preliminary studies, analysis and interpretation of data. J.H.: acquisition, analysis and interpretation of data. U.F.: analysis and interpretation of data. X.W.: analysis and interpretation of data. C.V.: acquisition and analysis of data.
provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Afanasyeva M, Georgakopoulos D, Belardi DF, Ransmundar AC, Barin JG, Kass DA, Rose NR (2004) Quantitative analysis of myocardial inflammation by flow cytometry in murine autoimmune myocarditis: correlation with cardiac function. Am J Pathol 164:807–815. https://doi.org/10.1016/S0002-9440(10)63169-0

2. Armstrong PC, Peter K (2012) GPIIb/IIIa inhibitors: from bench to bedside and back to bench again. Thromb Haemost 107:808–814. https://doi.org/10.1160/TH11-10-0727

3. Arnaout MA (2016) Biology and structure of leukocyte beta 2 integrins and their role in inflammation. F1000Res 5. https://doi.org/10.12688/F1000research.9415.1

4. Bagher P, Segal SS (2011) The mouse cremaster muscle preparation for intravital imaging of the microcirculation. J Vis Exp 10(52):2874

5. Baldwin ET, Sarver RW, Bryant GL Jr, Cannon CP, Finzel BC, Garlık RL, Heimrikson RL, Horton NC, Kelley LL, Meldner AM, Moon JB, Mott JE, Mutchler VT, Tomich CS, Watenpaugh KD, Wiley VH (1998) Cation binding to the integrin CD11b/CD18 in vitro and on human monocytes. J Biol Chem 273:8534–8539

6. Bazzoni G, Hämmerle ME (1998) Are changes in integrin affinity and conformation overemphasized? Trends Biochem Sci 23:30–34. https://doi.org/10.1016/S0968-0004(97)01141-9

7. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jimenez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sacco S, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JL, Wilkins J, Wu JH, Alger HM, Wong SS, Muntner P, American Heart Association. Circulation 135:e146–e603. https://doi.org/10.1161/CIR.0000000000000485

8. Benoit M, Gabrielle D, Gerisch G, Gaub HE (2000) Discrete interactions in cell adhesion measured by single-molecule force spectroscopy. Nat Cell Biol 2:313–317. https://doi.org/10.1038/35014000

9. Binz HK, Amstutz P, Kohl A, Stumpf MT, Briand C, Forrer P, Gruetter MG, Plückthun A (2004) High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol 22:575–582. https://doi.org/10.1038/nbt962

10. Binz HK, Amstutz P, Plückthun A (2005) Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 23:1257–1268. https://doi.org/10.1038/nbt1127

11. Bursi F, Weston SA, Killian JM, Gabriel SE, Jacobsen SJ, Roger VL (2007) C-reactive protein and heart failure after myocardial infarction in the community. Am J Med 120:616–622. https://doi.org/10.1016/j.amjmed.2006.07.039
12. Byron A, Humphries JD, Askari JA, Craig SE, Mould AP, Humphries MJ (2009) Anti-integrin monoclonal antibodies. J Cell Sci 122:4009–4011. https://doi.org/10.1242/jcs.056770

13. Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Helio T, Heymans S, Jahnns R, Klingel K, Linhart A, Maisch B, McKenna W, Mogensen J, Pinto YM, Ristic A, Schultheiss HP, Seggewiss H, Tavazzi L, Thiene G, Yilmaz A, Charron P, Elliott PM, European Society of Cardiology Working Group on Myocardial and Pericardial Diseases (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34:2636–2648, 2648a–2648d. https://doi.org/10.1093/eurheartj/eht210

14. Cavaillon JM, Singer M, Skirecki T (2020) Sepsis therapies: learning from 30 years of failure of translational research to propose new leads. EMBO Mol Med 12:e10128. https://doi.org/10.15252/emmm.201810128

15. Clackson T, Lowman H (2004) Phage display: a practical approach. Oxford University Press, Oxford

16. Cooper LT (2009) Myocarditis. N Engl J Med 360:1526–1538. https://doi.org/10.1056/NEJMra0800028

17. Cooper LT, Keren A, Sliwa K, Matsumori A, Mensah GA (2014) The global burden of myocarditis: part 1: a systematic literature review for the global burden of diseases, injuries, and risk factors 2010 study. Global Heart 9:121–129. https://doi.org/10.1016/j.ghart.2014.01.007

18. de Beer FC, Hind CR, Fox KM, Allan RM, Maseri A, Pepys MB (1982) Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J 47:47–52. https://doi.org/10.1136/hrt.47.3.239

19. Dehndi A, Benedict Cosimi A, Neal Smith R, Li X, Alonso JL, Means TK, Arnaout MA (2017) Prophylactic orthosteric inhibition of leucocyte integrin CD11b/CD18 prevents long-term fibrotic kidney failure in cynomolgus monkeys. Nat Commun 8:13899. https://doi.org/10.1038/ncomms13899

20. Diamond MS, Garcia-Aguilar J, Bickford JK, Corbi AL, Springer TA (1993) The I domain is a major recognition site on the leucocyte integrin Mac-1 (CD11b/CD18) for four distinct adhesion ligands. J Cell Biol 120:1031–1043. https://doi.org/10.1083/jcb.120.4.1031

21. Diamond MS, Springer TA (1993) A subpopulation of Mac-1 (CD11b/CD18) molecules mediates neutrophil adhesion to ICAM-1 and fibrinogen. J Cell Biol 120:545–556. https://doi.org/10.1083/jcb.120.2.545

22. Diamond MS, Staunton DE, de Fougerolles AR, Stackler SA, Garcia-Aguilar J, Hibbs ML, Springer TA (1990) ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18). J Cell Biol 111:3129–3139. https://doi.org/10.1083/jcb.111.6.3129

23. Dunne JL, Collins RG, Beaudet AL, Ballantyne CM, Ley K (2002) Mac-1, but not LFA-1, uses intercellular adhesion molecule-1 to mediate slow leukocyte rolling in TNFα-induced inflammation. J Immunol 171:6105–6111. https://doi.org/10.4049/jimmunol.171.11.6105

24. Eisenhardt SU, Schwartz M, Bassler N, Peter K (2007) Subtractive single-chain antibody (scFv) phage-display: tailoring phage-display for high specificity against function-specific conformations of cell membrane molecules. Nat Protoc 2:3063–3073. https://doi.org/10.1038/nprot.2007.455

25. Eisenhardt SU, Schwartz M, Schallner N, Soosairajah J, Bassler N, Huang D, Bode C, Peter K (2007) Generation of activation-specific human anti-alphaMbeta2 single-chain antibodies as potential diagnostic tools and therapeutic agents. Blood 109:3521–3528. https://doi.org/10.1182/blood-2006-03-007179

26. Fortenberry JD, Bhardwaj V, Niemer P, Cornish JD, Wright JA, Bland L (1996) Neutrophil and cytokine activation with neonatal extracorporeal membrane oxygenation. J Pediatr 128:670–678. https://doi.org/10.1016/s0022-3476(96)80133-8

27. Gavins FN, Chatterjee BE (2004) Intravital microscopy for the study of mouse microcirculation in anti-inflammatory drug research: focus on the mesentery and cremaster preparations. J Pharmacol Toxicol Methods 49:1–14. https://doi.org/10.1016/S1056-8719(03)00057-1

28. Gerhardt T, Ley K (2015) Monocyte trafficking across the vessel wall. Cardiovasc Res 107:321–330. https://doi.org/10.1093/cvr/cvv147

29. Global-Burden-of-Disease-Study-2013-Collaborators (2015) Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386:743–800. https://doi.org/10.1016/s0140-6736(15)60692-4

30. Gordon EJ, Myers KJ, Dougherty JP, Rosen H, Ron Y (1995) Both anti-CD11a (LFA-1) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis. J Neuroimmunol 62:153–160. https://doi.org/10.1016/0165-7789(95)00120-2

31. Graulich J, Walzog B, Marckincowski M, Bauer K, Kossel H, Fuhrmann G, Buhrer C, Gauchtgens P, Versmold HT (2000) Leukocyte and endothelial activation in a laboratory model of extracorporeal membrane oxygenation (ECMO). Pediatr Res 48:679–684. https://doi.org/10.1203/00006450-200011000-00021

32. Guillard S, Kolasinska-Zwierz P, Debreczeni J, Breed J, Zhang J, Berry N, Marwood R, Tart J, Overman R, Stocki P, Mistry B, Phillips C, Rabbitts T, Jackson R, Minter R (2017) Structural and functional characterization of a DARPIn which inhibits Ras nucleotide exchange. Nat Commun 8:16111–16111. https://doi.org/10.1038/ncomms16111

33. Hausenloy DJ, Yellon DM (2013) Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest 123:92–100. https://doi.org/10.1172/jci62874

34. Helenius J, Heisenberg CP, Gaub HE, Muller DJ (2008) Single-cell force spectroscopy. J Cell Sci 121:1785–1791. https://doi.org/10.1242/jcs.030999

35. Heusch G (2020) Myocardial ischemia-reperfusion injury and cardioprotection in perspective. Nat Rev Cardiol 17:773–789. https://doi.org/10.1038/s41569-020-0403-y

36. Hu X, Kang S, Lefort C, Kim M, Jin MM (2010) Combinatorial libraries against libraries for selecting neoeptope activation-specific antibodies. Proc Nat Acad Sci USA 107:6252–6257. https://doi.org/10.1073/pnas.0914358107

37. Ibáñez B, Heusch G, Ovize M, Van de Werf F (2015) Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol 65:1454–1471. https://doi.org/10.1016/j.jacc.2015.02.032

38. Inoue T, Sakai Y, Morooka S, Hayashi T, Takayanagi K, Takabatake Y (1996) Expression of polymorphonuclear leukocyte adhesion molecules and its clinical significance in patients treated with percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 28:1127–1133. https://doi.org/10.1016/s0735-1097(96)00308-7

39. Inwald DP, Kirkham PJ, Peters MJ, Lane R, Wade A, Evans JP, Klein NJ (2000) Platelet and leucocyte activation in childhood sickle cell disease: association with nocturnal hypoxaemia. Br J Haematol 111:474–481. https://doi.org/10.1046/j.1365-2141.2000.02353.x

40. Kinashi T (2006) Adhere uprift: a switchblade-like extension of beta2 integrins. Immunity 25:521–522. https://doi.org/10.1016/j.immuni.2006.09.002

41. Kindermann I, Kindermann M, Kandolf R, Klingel K, Bultmann B, Muller T, Lindinger A, Bohm M (2008) Predictors of outcome in patients with suspected myocarditis. Circulation
73. Tang T, Rosenkranz A, Assmann KJM, Goodman MJ, Gutierrez-Ramos J-C, Carroll MC, Cotran RS, Mayadas TN (1997) A role for Mac-1 (CD11b/CD18) in immune complex-stimulated neutrophil function in vivo: Mac-1 deficiency abrogates sustained Fcγ receptor-dependent neutrophil adhesion and complement-dependent proteinuria in acute glomerulonephritis. J Exp Med 186:1853–1863. https://doi.org/10.1084/jem.186.11.1853

74. Taylor PC, Chu CQ, Plater-Zyberk C, Maini RN (1996) Transfer of type II collagen-induced arthritis from DBA/1 to severe combined immunodeficiency mice can be prevented by blockade of Mac-1. Immunology 88:315–321. https://doi.org/10.1111/j.1365-2567.1996.tb00021.x

75. Todd RF 3rd (1996) The continuing saga of complement receptor type 3 (CR3). J Clin Invest 98:1–2. https://doi.org/10.1172/JCI118752

76. Ustinov VA, Plow EF (2002) Delineation of the key amino acids involved in neutrophil inhibitory factor binding to the I-domain supports a mosaic model for the capacity of integrin alphaMbeta2 to recognize multiple ligands. J Biol Chem 277:18769–18776. https://doi.org/10.1074/jbc.M110242200

77. Valaperti A, Marty RR, Kania G, Germano D, Mauermann N, Dirnhofer S, Leimenstoll B, Blyszczuk P, Dong C, Mueller C, Hunziker L, Eriksson U (2008) CD11b+ monocytes abrogate Th17 CD4+ T cell-mediated experimental autoimmune myocarditis. J Immunol 180:2686–2695. https://doi.org/10.4049/jimmunol.180.4.2686

78. Wetzel SK, Settanni G, Kenig M, Binz HK, Pluckthun A (2008) Folding and unfolding mechanism of highly stable full-consensus ankyrin repeat proteins. J Mol Biol 376:241–257. https://doi.org/10.1016/j.jmb.2007.11.046

79. Wolf D, Anto-Michel N, Blankenbach H, Wiedemann A, Buscher K, Hohmann JD, Lim B, Bäuml M, Marki A, Mauler M, Duerschmied D, Fan Z, Winkels H, Sidler D, Diehl P, Zajonc DM, Hilgendorf I, Stachon P, Marchini T, Willecke F, Schell M, Sommer B, von zur Muhlen C, Reinohl J, Gerhardt T, Plow EF, Yakubenko V, Libby P, Bode C, Ley K, Peter K, Zirlik A (2018) A ligand-specific blockade of the integrin Mac-1 selectively targets pathologic inflammation while maintaining protective host-defense. Nat Commun 9:525. https://doi.org/10.1038/s41467-018-02896-8

80. Wolf D, Hohmann JD, Wiedemann A, Bledzka K, Blankenbach H, Marchini T, Gutte K, Zeschky K, Bassler N, Hoppe N, Rodriguez AO, Herr N, Hilgendorf I, Stachon P, Willecke F, Duerschmied D, von zur Muhlen C, Soloviev DA, Zhang L, Bode C, Plow EF, Libby P, Peter K, Zirlik A (2011) Binding of CD40L to Mac-1’s I-domain involves the EQLKKSKTL motif and mediates leukocyte recruitment and atherosclerosis—but does not affect immunity and thrombosis in mice. Circ Res 109:1269–1279. https://doi.org/10.1161/CIRCRESAHA.111.247684

81. Wolf D, Ley K (2019) Immunity and inflammation in atherosclerosis. Circ Res 124:315–327. https://doi.org/10.1161/CIRCRESAHA.118.313591

82. Ye F, Kim C, Ginsberg MH (2012) Reconstruction of integrin activation. Blood 119:26–33. https://doi.org/10.1182/blood-2011-04-292128

83. Zaldivia MT, Rivera J, Hering D, Marusic P, Sata Y, Lim B, Eikelis N, Lee R, Lambert GW, Esler MD, Hun NM, Duval J, Hammond L, Eisenhardt SU, Flierl U, Schlaich MP, Peter K (2017) Renal denervation reduces monocyte activation and monocyte-platelet aggregate formation: an anti-inflammatory effect relevant for cardiovascular risk. Hypertension 69:323–331. https://doi.org/10.1161/HYPERTENSIONAHA.116.08373

84. Ziegler M, Hohmann JD, Searle AK, Abraham M-K, Nandurkar HH, Wang X, Peter K (2018) A single-chain antibody-CD39 fusion protein targeting activated platelets protects from cardiac ischaemia/reperfusion injury. Eur Heart J 39:111–116. https://doi.org/10.1093/eurheartj/ehx218
Author/s:
Siegel, PM; Bojti, I; Bassler, N; Holien, J; Flierl, U; Wang, X; Waggershauser, P; Tonnar, X; Vedecnik, C; Lamprecht, C; Stankova, I; Li, T; Helbing, T; Wolf, D; Anto-Michel, N; Mitre, LS; Ehrlich, J; Orlean, L; Bender, I; Przewosnik, A; Mauler, M; Hollederer, L; Moser, M; Bode, C; Parker, MW; Peter, K; Diehl, P

Title:
A DARPin targeting activated Mac-1 is a novel diagnostic tool and potential anti-inflammatory agent in myocarditis, sepsis and myocardial infarction

Date:
2021-03-15

Citation:
Siegel, P. M., Bojti, I., Bassler, N., Holien, J., Flierl, U., Wang, X., Waggershauser, P., Tonnar, X., Vedecnik, C., Lamprecht, C., Stankova, I., Li, T., Helbing, T., Wolf, D., Anto-Michel, N., Mitre, L. S., Ehrlich, J., Orlean, L., Bender, I., ... Diehl, P. (2021). A DARPin targeting activated Mac-1 is a novel diagnostic tool and potential anti-inflammatory agent in myocarditis, sepsis and myocardial infarction. BASIC RESEARCH IN CARDIOLOGY, 116 (1), https://doi.org/10.1007/s00395-021-00849-9.

Persistent Link:
http://hdl.handle.net/11343/274026

File Description:
Published version

License:
CC BY